Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

Video

In Partnership With:

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Most patients with CLL receive treatment with small molecule inhibitors throughout the entire course of their disease, says Woyach. 

Standard treatment​s include ​BTK inhibitors such as ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa)​, explains Woyach. In addition, venetoclax ​(Venclexta), a BCL​-2 inhibitor, in combination with obinutuzumab (Gazyva) or rituximab (Rituxan) is another option in the space. 

Moreover, reversible BTK inhibitors have shown encouraging preliminary efficacy ​in CLL, Woyach concludes. 

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD